• Ultragenyx Pharmaceutical Inc. reported past first-quarter 2026 results with revenue of US$136 million, a wider net loss of US$185 million, and reaffirmed its 2026 revenue guidance of US$730 million to US$760 million while remaining on a stated path toward profitability in 2027.
• Management also highlighted potential 2026 approvals for two gene therapies and key late-stage data for its Angelman syndrome program, underscoring how clinical and regulatory milestones are central to its longer-term earnings ambitions.
• Next, we’ll examine how reaffirmed 2026 revenue guidance, despite weaker quarterly results, affects Ultragenyx’s profitability-focused investment narrative and risk profile.

Outshine the giants: these 16 early-stage AI stocks could fund your retirement.

Ultragenyx Pharmaceutical Investment Narrative Recap

To own Ultragenyx, you need to believe that its rare disease and gene therapy pipeline can transition the company from heavy losses to sustainable profitability, with upcoming approvals and data readouts unlocking meaningful revenue from a small, concentrated set of assets. The Q1 2026 miss and wider net loss do not materially change the near term focus on 2026 regulatory decisions for DTX401 and UX111, but they do sharpen attention on cash burn and execution risk around that 2027 profitability goal.

The most relevant recent update is management’s reaffirmation of 2026 revenue guidance of US$730 million to US$760 million despite weaker Q1 results. That stance, paired with anticipated PDUFA decisions for DTX401 and UX111 and Phase 3 GTX-102 data in the second half of 2026, keeps the story centered on whether clinical and regulatory milestones can translate into the revenue scale needed to offset ongoing losses and support the stated path to profitability.

Yet, while the company highlights a clear route to 2027 profitability, investors should also be aware that...

Ultragenyx Pharmaceutical's narrative projects $1.3 billion revenue and $69.1 million earnings by 2029.

Uncover how Ultragenyx Pharmaceutical's forecasts yield a $52.45 fair value, a 101% upside to its current price.

Exploring Other Perspectives

By contrast, the most pessimistic analysts were assuming slower revenue growth near 12.8 percent and no profitability within three years, so this reaffirmed 2026 guidance may either challenge or reinforce their concern that heavy losses and pipeline concentration could still keep earnings under pressure even if some milestones arrive on time.

Explore 2 other fair value estimates on Ultragenyx Pharmaceutical - why the stock might be worth over 10x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Ultragenyx Pharmaceutical research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Ultragenyx Pharmaceutical research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ultragenyx Pharmaceutical's overall financial health at a glance.

Looking For Alternative Opportunities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Capitalize on the AI infrastructure supercycle with our selection of the 40 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.